1. Home
  2. COHN vs BOLT Comparison

COHN vs BOLT Comparison

Compare COHN & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COHN
    SELLHOLDBUYas of 9 hours ago
  • BOLT
    SELLHOLDBUYas of 9 hours ago
  • Stock Information
  • Founded
  • COHN 1999
  • BOLT 2015
  • Country
  • COHN United States
  • BOLT United States
  • Employees
  • COHN N/A
  • BOLT N/A
  • Industry
  • COHN Investment Bankers/Brokers/Service
  • BOLT Biotechnology: Pharmaceutical Preparations
  • Sector
  • COHN Finance
  • BOLT Health Care
  • Exchange
  • COHN Nasdaq
  • BOLT Nasdaq
  • Market Cap
  • COHN 17.8M
  • BOLT 16.8M
  • IPO Year
  • COHN N/A
  • BOLT 2021
  • Fundamental
  • Price
  • COHN $6.50
  • BOLT $0.35
  • Analyst Decision
  • COHN
  • BOLT Hold
  • Analyst Count
  • COHN 0
  • BOLT 5
  • Target Price
  • COHN N/A
  • BOLT $1.13
  • AVG Volume (30 Days)
  • COHN 9.2K
  • BOLT 166.8K
  • Earning Date
  • COHN 05-05-2025
  • BOLT 05-13-2025
  • Dividend Yield
  • COHN 15.55%
  • BOLT N/A
  • EPS Growth
  • COHN N/A
  • BOLT N/A
  • EPS
  • COHN N/A
  • BOLT N/A
  • Revenue
  • COHN $73,777,000.00
  • BOLT $7,690,000.00
  • Revenue This Year
  • COHN N/A
  • BOLT N/A
  • Revenue Next Year
  • COHN N/A
  • BOLT $77.45
  • P/E Ratio
  • COHN N/A
  • BOLT N/A
  • Revenue Growth
  • COHN N/A
  • BOLT N/A
  • 52 Week Low
  • COHN $6.10
  • BOLT $0.30
  • 52 Week High
  • COHN $12.82
  • BOLT $1.34
  • Technical
  • Relative Strength Index (RSI)
  • COHN 20.24
  • BOLT 40.56
  • Support Level
  • COHN $6.75
  • BOLT $0.30
  • Resistance Level
  • COHN $7.52
  • BOLT $0.39
  • Average True Range (ATR)
  • COHN 0.48
  • BOLT 0.04
  • MACD
  • COHN -0.18
  • BOLT -0.00
  • Stochastic Oscillator
  • COHN 0.00
  • BOLT 26.63

Stock Price Comparison Chart: COHN vs BOLT

COHN
BOLT
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April0510152025303540COHN VS BOLT

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use